Genolution

Genolution EPS

The Earnings per Share (EPS) of Genolution (225220.KQ) as of Oct 22, 2026 is -644.05 KRW. In the previous year, Earnings per Share (EPS) was -378.02 KRW — a change of 70.37% (lower).

EPS

-644.05KRW

YoY

70.37%

Last updated:

Earnings per Share (EPS) of Genolution is 2025 -644.05 KRW. Earnings per Share (EPS) of Genolution was 2024 -378.02 KRW. It decreases by 70.37% lower compared to the previous year.

The Genolution EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
203.26 KRW
Jan 1, 2019
-47.72 KRW
Jan 1, 2020
3,349.59 KRW
Jan 1, 2021
1,881.28 KRW
Jan 1, 2022
808.90 KRW
Jan 1, 2023
-307.40 KRW
Jan 1, 2024
-378.02 KRW
Jan 1, 2025
-644.05 KRW
The Genolution EPS history
YEAREPSYoY
-644.05KRW+70.37%
-378.02KRW+22.98%
-307.40KRW-138.00%
808.90KRW-57.00%
1,881.28KRW-43.84%
3,349.59KRW-7,118.94%
-47.72KRW-123.48%
203.26KRW+106.12%
98.61KRW+535.88%
15.51KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Earnings per Share (EPS) of Genolution is -644.05 KRW in 2025.

Earnings per Share (EPS) of Genolution changed from -378.02 KRW to -644.05 KRW, representing a 70.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Genolution since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genolution

All Key Metrics — Genolution